Patient experience of alpha-1 antitrypsin deficiency-associated liver disease: a qualitative study
Rattachement africain : us, jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE: To elicit the signs and/or symptoms, and impacts on daily living experienced by patients with alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD). METHODS: A preliminary "concept list" of signs and/or symptoms, and impacts was developed from a targeted literature review, patient blog posts, and clinician interviews. Subsequently, one-to-one concept elicitation interviews involving English-speaking, US adults with AATD-LD and a protease inhibitor (Pi) ZZ or MZ genotype were conducted by trained interviewers following a central Institutional Review Board-approved discussion guide. An AATD-LD conceptual model was developed based on these findings. Concepts were "most salient" if reported by ≥ 8 patients with a mean bothersomeness/disturbance rating of ≥ 5, or "highly salient" if reported by > 5- < 8 patients with a mean bothersomeness/disturbance rating of ≥ 5 (scale: 0-10, 0: not at all bothersome/disturbing; 10: extremely bothersome/disturbing). RESULTS: Fifteen patients were interviewed (median [range] age: 57 [28-78] years; Pi*ZZ, n = 12; Pi*MZ, n = 3). Of 41 signs and/or symptoms, the most salient were fatigue/tiredness, respiratory infections, shortness of breath, confusion/difficulty concentrating, and edema. Highly salient signs and/or symptoms were abdominal swelling, acid reflux, sleep disturbance, vomiting, abdominal pain/tenderness, itchiness, and back pain. Of 16 impacts, the most salient were on work and employment, leisure activities, and relationships. Impacts on mobility were highly salient. CONCLUSION: Several concepts were frequently reported as moderately/highly bothersome/disturbing. Further investigation of the experience of patients with AATD-LD in a large, diverse population across all fibrosis stages and genotypes is warranted. Clinical outcome assessments that capture salient concepts are needed.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Patient experience of alpha-1 antitrypsin deficiency-associated liver disease: a qualitative study
- Date Crossref
- 13/03/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Florida pays non établi dans la noticeUniversité ou école supérieure
-
Takeda (United States) pays non établi dans la noticeEntreprise
-
IQVIA (United States) pays non établi dans la noticeEntreprise
-
IQ Solutions pays non établi dans la noticeEntreprise
-
Takeda (Japan) pays non établi dans la noticeEntreprise
-
Creighton University pays non établi dans la noticeUniversité ou école supérieure
-
St. Joseph's Hospital and Medical Center pays non établi dans la noticeÉtablissement de santé
-
University School pays non établi dans la noticeUniversité ou école supérieure
-
Inc. Takeda Development Center Americas pays non établi dans la noticeEntreprise
-
IQVIA Patient Centered Solutions pays non établi dans la noticeInstitution
University of Florida, Takeda (United States) et IQVIA (United States), avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.